Cargando…
Primum non nocere – Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)?
Chloroquine (CQ) and its analog hydroxychloroquine (HCQ) were recently included in several clinical trials as potential prophylactic and therapeutic options for SARS-COV-2 infection/covid-19. However, drug effectiveness in preventing, treating, or slowing the progression of the disease is still unkn...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Faculdade de Saúde Pública da Universidade de São Paulo
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319500/ https://www.ncbi.nlm.nih.gov/pubmed/32638884 http://dx.doi.org/10.11606/s1518-8787.2020054002631 |
_version_ | 1783551064102928384 |
---|---|
author | Biguetti, Claudia Marrelli, Mauro Toledo Brotto, Marco |
author_facet | Biguetti, Claudia Marrelli, Mauro Toledo Brotto, Marco |
author_sort | Biguetti, Claudia |
collection | PubMed |
description | Chloroquine (CQ) and its analog hydroxychloroquine (HCQ) were recently included in several clinical trials as potential prophylactic and therapeutic options for SARS-COV-2 infection/covid-19. However, drug effectiveness in preventing, treating, or slowing the progression of the disease is still unknown. Despite some initial promising in vitro results, rigorous pre-clinical animal studies and randomized clinical trials have not been performed yet. On the other hand, while the potential effectiveness of CQ/HCQ is, at best, hypothetical, their side effects are factual and most worrisome, particularly when considering vulnerable groups of patients being treated with these drugs. in this comment, we briefly explain the possible mechanisms of action of CQ/HCQ for treating other diseases, possible actions against covid-19, and their potent side effects, in order to reinforce the necessity of evaluating the benefit-risk balance when widely prescribing these drugs for SARS-COV-2 infection/covid-19. We conclude by strongly recommending against their indiscriminate use. |
format | Online Article Text |
id | pubmed-7319500 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Faculdade de Saúde Pública da Universidade de São Paulo |
record_format | MEDLINE/PubMed |
spelling | pubmed-73195002020-07-06 Primum non nocere – Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)? Biguetti, Claudia Marrelli, Mauro Toledo Brotto, Marco Rev Saude Publica Comment Chloroquine (CQ) and its analog hydroxychloroquine (HCQ) were recently included in several clinical trials as potential prophylactic and therapeutic options for SARS-COV-2 infection/covid-19. However, drug effectiveness in preventing, treating, or slowing the progression of the disease is still unknown. Despite some initial promising in vitro results, rigorous pre-clinical animal studies and randomized clinical trials have not been performed yet. On the other hand, while the potential effectiveness of CQ/HCQ is, at best, hypothetical, their side effects are factual and most worrisome, particularly when considering vulnerable groups of patients being treated with these drugs. in this comment, we briefly explain the possible mechanisms of action of CQ/HCQ for treating other diseases, possible actions against covid-19, and their potent side effects, in order to reinforce the necessity of evaluating the benefit-risk balance when widely prescribing these drugs for SARS-COV-2 infection/covid-19. We conclude by strongly recommending against their indiscriminate use. Faculdade de Saúde Pública da Universidade de São Paulo 2020-06-26 /pmc/articles/PMC7319500/ /pubmed/32638884 http://dx.doi.org/10.11606/s1518-8787.2020054002631 Text en https://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Comment Biguetti, Claudia Marrelli, Mauro Toledo Brotto, Marco Primum non nocere – Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)? |
title | Primum non nocere – Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)? |
title_full | Primum non nocere – Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)? |
title_fullStr | Primum non nocere – Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)? |
title_full_unstemmed | Primum non nocere – Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)? |
title_short | Primum non nocere – Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)? |
title_sort | primum non nocere – are chloroquine and hydroxychloroquine safe prophylactic/treatment options for sars-cov-2 (covid-19)? |
topic | Comment |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319500/ https://www.ncbi.nlm.nih.gov/pubmed/32638884 http://dx.doi.org/10.11606/s1518-8787.2020054002631 |
work_keys_str_mv | AT biguetticlaudia primumnonnocerearechloroquineandhydroxychloroquinesafeprophylactictreatmentoptionsforsarscov2covid19 AT marrellimaurotoledo primumnonnocerearechloroquineandhydroxychloroquinesafeprophylactictreatmentoptionsforsarscov2covid19 AT brottomarco primumnonnocerearechloroquineandhydroxychloroquinesafeprophylactictreatmentoptionsforsarscov2covid19 |